More T cell receptors to the RAScue in cancer?

Abstract excerpt

Treatment with T cells genetically engineered to express tumor-reactive T cell receptors (TCRs), known as TCR-gene therapy (TCR-T), is a promising immunotherapeutic approach for patients with cancer. The identification of optimal TCRs to use and tumor antigens to target are key considerations for TCR-T. In this issue of the JCI, Bear and colleagues report on their use of in vitro assays to characterize four...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antigens, Neoplasm
• Share to Cancer Vaccines
• Share to HLA-A Antigens